LAB TESTING
7 Tests Before GLP-1 Medication That May Be Considered
Short answer: Tests before GLP-1 medication are individualized. A provider may review weight and blood pressure, blood glucose or A1c, kidney and liver function, lipids, and a pregnancy test when relevant. Medical history and current medications are just as important as laboratory values.
There is no single mandatory panel for every patient beginning semaglutide or tirzepatide. Testing should answer a clinical question: confirm an indication, establish a useful baseline, identify a safety concern, or guide another medication that may need adjustment.
Why baseline testing matters
GLP-1–based medicines affect appetite, food intake, gastric emptying, and glucose regulation. Nausea, vomiting, or diarrhea can contribute to dehydration, which may worsen kidney problems. Diabetes medicines may also require adjustment as glucose improves.
A baseline does not guarantee that a medication will be tolerated, but it gives the clinician a clearer starting point for treatment and follow-up.
7 tests before GLP-1 medication that may help
1. Weight, BMI, and waist-related assessment
Weight and height help determine whether the patient meets the labeled indication for chronic weight management. Waist circumference may add information about cardiometabolic risk, although it is not required in every workflow.
2. Blood pressure and pulse
These are not blood tests, but they are important baseline measurements. Weight change, dehydration, and other medications can affect blood pressure, and some patients need closer monitoring.
3. Hemoglobin A1c or fasting glucose
A1c estimates average glucose over the previous several months. It can identify diabetes or prediabetes and help the provider safely coordinate insulin, sulfonylureas, or other glucose-lowering treatment.
4. Kidney function and electrolytes
Creatinine, estimated glomerular filtration rate, and electrolytes may be useful when there is kidney disease, hypertension, diabetes, diuretic use, or concern about dehydration. Repeat testing may be appropriate if significant gastrointestinal symptoms occur.
5. Liver-related tests
ALT, AST, bilirubin, and other components of a metabolic panel can help evaluate general health or suspected fatty liver disease. Abnormal results do not automatically rule treatment in or out; they require interpretation.
6. Lipid panel
Cholesterol and triglycerides help define cardiovascular risk and provide a baseline for the broader weight-management plan. Very high triglycerides may also change how a clinician interprets abdominal symptoms and pancreatitis risk.
7. Pregnancy testing when relevant
Weight-management doses of semaglutide and tirzepatide should not be used during pregnancy. Patients who could become pregnant should discuss contraception, pregnancy plans, and when the medication must be stopped before trying to conceive.
Tests that are not automatically required
Thyroid testing may be appropriate when symptoms or history suggest thyroid dysfunction, but TSH does not screen for medullary thyroid carcinoma. The FDA labels state that routine calcitonin testing or thyroid ultrasound is of uncertain value for early detection in patients treated with these medications.
Amylase and lipase are also not useful as automatic screening tests for every asymptomatic patient. A history of pancreatitis or new, persistent severe abdominal pain requires individual evaluation.
History questions that matter as much as labs
- Personal or family history of medullary thyroid carcinoma or MEN 2
- Previous pancreatitis or gallbladder disease
- Kidney disease or recurrent dehydration
- Severe gastrointestinal disease or gastroparesis symptoms
- Diabetes and all glucose-lowering medications
- Pregnancy, breastfeeding, contraception, and pregnancy plans
- Current compounded, injectable, or weight-loss products
- Eating-disorder history or difficulty meeting nutritional needs
Frequently asked questions
Can treatment start without laboratory testing?
The answer depends on the patient, medication, indication, and available recent results. A provider may need updated testing to make a safe decision or may determine that specific tests are unnecessary.
Are thyroid labs required before semaglutide or tirzepatide?
Not solely because the medication is being considered. Thyroid evaluation is based on symptoms, history, examination, and clinical judgment. Patients must still disclose a personal or family history of medullary thyroid carcinoma or MEN 2.
How often are tests repeated?
Follow-up is tailored to diabetes status, kidney risk, symptoms, medication changes, and baseline abnormalities. Weight, tolerability, nutrition, and medication adherence are often reviewed more frequently than broad laboratory panels.
Medical Weight-Loss Evaluation
Ready for a complete baseline review?
Magnum Health reviews health history, medications, goals, and appropriate testing before prescribing weight-management treatment to eligible Texas patients.
Start a Semaglutide Evaluation
Eligibility and treatment are determined following an individual medical evaluation.
This article is for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment. Testing and treatment decisions vary by patient.